Cencora stock heads into the open after a 0.1% dip
Published on 09/11/2026 at 04:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cencora stock closed at USD 324.22 on the NYSE on September 9, 2026, down 0.1% from the prior session. The move kept the shares comfortably within their 52-week range between USD 244.82 and USD 377.54, with the latest session price sitting in the upper half of that band.
September 9, 2026 in numbers
Cencora Inc. (ISIN US15135B1017, NYSE: COR) ended the September 9, 2026 session at USD 324.22 after a intraday range between USD 322.17 and USD 326.99, according to MarketBeat data for the NYSE listing. Per the same overview from MarketBeat, the 52-week range for the stock stood between USD 244.82 on the low side and USD 377.54 on the high side, indicating that the latest close was roughly USD 79.40 above the 52-week low and about USD 53.32 below the 52-week high.MarketBeat also reported that trading volume in the last session came to 451,092 shares, below the average daily volume of about 1.51 million shares for Cencora, which points to a relatively quieter day in terms of turnover.
The broader market weakened on September 10, 2026, with the S&P 500 falling 0.6% to 7,591.70 as higher oil prices weighed on sentiment, as described by Las Vegas Sun. With Cencora’s modest decline of 0.1% in the previous session and its position near the upper end of its 52-week range, the stock remained more resilient than the broad index over that two-day span.
Today’s catalysts around Cencora
Looking ahead to today, September 11, 2026, Cencora enters the final weeks of its fiscal year, which ends on September 30, 2026, according to the company calendar shown by MarketBeat. The next earnings release for Cencora is estimated for November 4, 2026, so today’s trading may instead respond to sector and market signals rather than a company-specific data point. Broader sentiment could be influenced by the recent pullback in major US indexes and movements in healthcare-related peers highlighted in recent portfolio and sector coverage from outlets such as Zacks Investment Research, which underscores that investors remain attentive to momentum and valuation across large healthcare distributors. Against this backdrop, Cencora’s share price level relative to its 52-week range and the broader index performance sets the stage for today’s session.
